The Myocet/Lapatinib Study. ICORG 10-03, V5
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Her2 Positive Metastatic Breast Cancer
Interventions: DRUG: non-pegylated liposomal doxorubicon (Myocet™)|DRUG: Lapatinib (Tyverb™)
Sponsor: Cancer Trials Ireland